Adicet Bio (ACET) Competitors

Adicet Bio (NASDAQ:ACET) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Do insiders & institutionals hold more shares of ACET or ADMA?

83.9% of Adicet Bio shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 7.8% of Adicet Bio shares are owned by insiders. Comparatively, 3.5% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has preferable valuation & earnings, ACET or ADMA?

ADMA Biologics has higher revenue and earnings than Adicet Bio. Adicet Bio is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	$24.99M	2.51	-$117.12M	-$1.30	-0.58
ADMA Biologics	$426.45M	9.37	$197.67M	$0.85	19.68

Which has more risk & volatility, ACET or ADMA?

Adicet Bio has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Is ACET or ADMA more profitable?

ADMA Biologics has a net margin of 45.01% compared to Adicet Bio's net margin of 0.00%. ADMA Biologics' return on equity of 47.16% beat Adicet Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-59.05%	-50.66%
ADMA Biologics	45.01%	47.16%	30.51%

Do analysts prefer ACET or ADMA?

Adicet Bio presently has a consensus price target of $7.50, suggesting a potential upside of 887.49%. ADMA Biologics has a consensus price target of $27.67, suggesting a potential upside of 65.37%. Given Adicet Bio's higher possible upside, equities research analysts clearly believe Adicet Bio is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media prefer ACET or ADMA?

In the previous week, ADMA Biologics had 4 more articles in the media than Adicet Bio. MarketBeat recorded 5 mentions for ADMA Biologics and 1 mentions for Adicet Bio. ADMA Biologics' average media sentiment score of 1.06 beat Adicet Bio's score of 1.05 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adicet Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ADMA Biologics beats Adicet Bio on 12 of the 17 factors compared between the two stocks.